12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PF-05280602: Phase I started

Catalyst said Pfizer began an open-label Phase I trial to evaluate single doses of 0.5, 1.5, 4.5, 9, 18 and 30 µg/kg IV PF-05280602 in about 36 adults with hemophilia...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >